Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274096 | 0.82 | HRH3 (0.55) | SMN1; SMN2HTTRECQLMAPTHRH3 | |
| SCHEMBL6098631 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTRECQLMAPTLMNA | |
| SCHEMBL15829990 | 0.81 | FPR2 (0.59) | SMN1; SMN2MAPTCYP2D6HRH3RORC | |
| SCHEMBL16038107 | 0.81 | HRH3 (0.56) | SMN1; SMN2MAPTCYP2D6HRH3RORC | |
| SCHEMBL27935616 | 0.80 | SIGMAR1 (0.67) | SMN1; SMN2HTTRECQLMAPTLMNA | |
| SCHEMBL11044966 | 0.80 | EPHX2 (0.54) | SMN1; SMN2MAPTLMNAALDH1A1KMT2A | |
| SCHEMBL6792850 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTRECQLMAPTLMNA | |
| SCHEMBL5864825 | 0.80 | ALDH1A1 (0.51) | SMN1; SMN2RECQLMAPTCYP2D6LMNA | |
| SCHEMBL18183745 | 0.80 | HRH3 (0.55) | SMN1; SMN2MAPTCYP2D6HRH3RORC | |
| SCHEMBL16532717 | 0.80 | SIGMAR1 (0.45) | SMN1; SMN2HTTRECQLMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970116-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| CN-105121404-A | Aryl sulfonamide and sulfamic acid derivatives as RORc modulators | HOFFMANN LA ROCHE | 2015-12-02 | — | — | CN | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014140059-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1216056-C | Sulfamidohydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| CN-1362954-A | Sulfamidohydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-08-07 | — | — | CN | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | MMP14, MMP12, MMP17 | SMN1; SMN2 1211/4885HTT 1335/4885RECQL 4295/4885 |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | RORA, RORC, RORB | SMN1; SMN2 2976/4885HTT 3771/4885RECQL 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.